

DAFTAR PUSTAKA

Abbas, A.K., Lichtman, A.H. and Pillai, S., 2012. *Basic immunology: functions and disorders of the immune system*. Elsevier Health Sciences.

Abe, M., Hiasa, Y. and Onji, M. (2013). T Helper 17 Cells in Autoimmune Liver Diseases. *Clinical and Developmental Immunology*, 2013, pp.1-6.

Abou-Shady, M., Friess, H., Zimmermann, A., Mola, F.F., Guo, X.Z., Baer, H.U. and Büchler, M.W., 2000. Connective tissue growth factor in human liver cirrhosis. *Liver*, 20(4), pp.296-304.

Akbar HN (2007). Hepatitis B dan Hepatitis C. Dalam : Sulaiman A. Akbar HN. Lesmana LA. Noer MS. Ed: *Buku Ajar Penyakit Hati*. Edisi 1. Jakarta: FK UI; 201-8

Alrawaiq, N.S. and Abdullah, A., 2014. A Review of Antioxidant Polyphenol Curcumin and its Role in Detoxification. *Int J Pharm Tech Res*, 6(1). 280-89.

Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Sung, B., Tharakan, S.T., Misra, K., Priyadarsini, I.K., Rajasekharan, K.N. and Aggarwal, B.B., 2008. Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. *Biochemical pharmacology*, 76(11), pp.1590-1611.

Alves, V.A., Bacchi, C.E. and Vassallo, J.O.S.É., 1999. Manual de imunohistoquímica. *São Paulo: Sociedade Brasileira de Patologia*, 270.

Anom, T. and Wibawa, D. (2010). Pendekatan Diagnosis dan Terapi Fibrosis Hati. *Jurnal Penyakit Dalam*, 11(1), pp.57-66.

Asai, A. and Miyazawa, T., 2000. Occurrence of orally administered curcuminoid as glucuronide and glucuronide/sulfate conjugates in rat plasma. *Life sciences*, 67(23), pp.2785-2793.

Baranova, A., Lal, P., Biredinc, A. and Younossi, Z. (2011). Non-Invasive markers for hepatic fibrosis. *BMC Gastroenterology*, 11(1), p.91.

Bataller, R. and Brenner, D. (2005). Liver fibrosis. *Journal of Clinical Investigation*, 115(2), pp.209-218.

Bhala, N., Angulo, P., van der Poorten, D., Lee, E., Hui, J., Saracco, G., Adams, L., Charatcharoenwitthaya, P., Topping, J., Bugianesi, E., Day, C. and George, J. (2011). The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study. *Hepatology*, 54(4), pp.1208-1216.

Bissell, D.M., Wang, S.S., Jarnagin, W.R. and Roll, F.J., 1995. Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. *Journal of Clinical Investigation*, 96(1), p.447.

Burgos-Morón, E., Calderón-Montaño, J.M., Salvador, J., Robles, A. and López-Lázaro, M., 2010. The dark side of curcumin. *International journal of cancer*, 126(7), pp.1771-1775.

Carroll, R.E., Benya, R.V., Turgeon, D.K., Vareed, S., Neuman, M., Rodriguez, L., Kakarala, M., Carpenter, P.M., McLaren, C., Meyskens, F.L. and Brenner, D.E., 2011. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. *Cancer Prevention Research*, 4(3), pp.354-364.

Chang, S., Park, H. and Dong, C. (2006). Act1 Adaptor Protein Is an Immediate and Essential Signaling Component of Interleukin-17 Receptor. *Journal of Biological Chemistry*, 281(47), pp.35603-35607.

Chen, A. and Zheng, S., 2008. Curcumin inhibits connective tissue growth factor gene expression in activated hepatic stellate cells in vitro by blocking NF- κ B and ERK signalling. *British journal of pharmacology*, 153(3), pp.557-567.

Date, M., Matsuzaki, K., Matsushita, M., Tahashi, Y., Furukawa, F. and Inoue, K., 2000. Modulation of transforming growth factor β function in hepatocytes and hepatic stellate cells in rat liver injury. *Gut*, 46(5), pp.719-724.

De Alwis, N.M.W. and Day, C.P., 2008. Non-alcoholic fatty liver disease: the mist gradually clears. *Journal of Hepatology*, 48, pp.S104-S112.

De Bleser, P.J., Niki, T., Rogiers, V. and Geerts, A., 1997. Transforming growth factor- β gene expression in normal and fibrotic rat liver. *Journal of hepatology*, 26(4), pp.886-893.

Deshpande, S.S., Lalitha, V.S., Ingle, A.D., Raste, A.S., Gadre, S.G. and Maru, G.B., 1998. Subchronic oral toxicity of turmeric and ethanolic turmeric extract in female mice and rats. *Toxicology Letters*, 95(3), pp.183-193.

Dixon, M., Agius, L., Yeaman, S.J. and Day, C.P., 1999. Inhibition of rat hepatocyte proliferation by transforming growth factor β and glucagon is

associated with inhibition of ERK2 and p70 S6 kinase. *Hepatology*, 29(5), pp.1418-1424.

Dooley, S., Delvoux, B., Lahme, B., Mangasser-Stephan, K. and Gressner, A.M., 2000. Modulation of transforming growth factor b response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. *Hepatology*, 31(5), pp.1094-1106.

Dooley, S., Dijke, P. (2011). *TGF- β in Progression of Liver Disease*. Cell Tissue Research. 347(1): 245–256

Fabregat, I., Moreno-Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G. and Dijke, P., 2016. TGF- β signalling and liver disease. *FEBS Journal*.

Faroon, O., 2005. *Toxicological profile for carbon tetrachloride*. Agency for Toxic Substances and Disease Registry.

Farrington, C., Novak, D., Liu, C. and Haafiz, A.B., 2010. Immunohistochemical localization of transforming growth factor β -1 and its relationship with collagen expression in advanced liver fibrosis due to biliary atresia. *Clinical and experimental gastroenterology*, 3, p.185.

Friedman, S. (2010). Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol*, 7(8), pp.425-436.

Fu, Y., Zheng, S., Lin, J., Ryerse, J. & Chen, A. 2008. Curcumin Protects the Rat Liver from CCl₄-Caused Injury and Fibrogenesis by Attenuating Oxidative Stress and Suppressing Inflammation. *Molecular Pharmacology* 73 (2), 399-409.

Garcea, G., Berry, D.P., Jones, D.J., Singh, R., Dennison, A.R., Farmer, P.B., Sharma, R.A., Steward, W.P. and Gescher, A.J., 2005. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. *Cancer Epidemiology Biomarkers & Prevention*, 14(1), pp.120-125.

Ganiger, S., Mallesappa, H.N., Krishnappa, H., Rajashekhar, G., Rao, V.R. and Sullivan, F., 2007. A two generation reproductive toxicity study with curcumin, turmeric yellow, in Wistar rats. *Food and chemical toxicology*, 45(1), pp.64-69

Gressner, A.M., Weiskirchen, R., Breitkopf, K. and Dooley, S., 2002. Roles of TGF-beta in hepatic fibrosis. *Front Biosci*, 7(1), pp.d793-807.

Goodman, Z. (2007). Grading and staging systems for inflammation and fibrosis in chronic liver diseases. *Journal of Hepatology*, 47(4), pp.598-607.

Gupta, S.C., Patchva, S. and Aggarwal, B.B., 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. *The AAPS journal*, 15(1), pp.195-218.

Hammerich, L., Heymann, F. and Tacke, F. (2011). Role of IL-17 and Th17 Cells in Liver Diseases. *Clinical and Developmental Immunology*, 2011, pp.1-12.

Halliwell, B.A.G.J. and Gutteridge, J.M., 1999. Oxygen is a toxic gas: an introduction to oxygen toxicity and reactive oxygen species. *Free radicals in biology and medicine*, 3, pp.1-35.

Holder, G.M., Plummer, J.L. and Ryan, A.J., 1978. The metabolism and excretion of curcumin (1, 7-bis-(4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione) in the rat. *Xenobiotica*, 8(12), pp.761-768.

Padauleng, N. and Nurhidayati, N., 2016. Holothuria scabra Memperbaiki Fibrosis Hepar pada Tikus yang Diinduksi Karbon Tetraklorida. *Jurnal Kedokteran Brawijaya*, 29(2), pp.139-142

Hidayatul, M. 2008. *Pengaruh Pemberian Buah Pepaya (Carica papaya) Terhadap Kadar Enzim Transaminase GOT-GPT dan Gambaran Histologi Hepar Mencit (Mus musculus) yang Diinduksi Karbontetraklorida (ccl)*. Skripsi. Fakultas Sains dan Teknologi. Malang

Ismail, M. and Pinzani, M. (2009). Reversal of liver fibrosis. *Saudi Journal of Gastroenterology*, 15(1), p.72.

Iredale, J.P., 1997. Tissue inhibitors of metalloproteinases in liver fibrosis. *The international journal of biochemistry & cell biology*, 29(1), pp.43-54.

Ireson, C., Orr, S., Jones, D.J., Verschoyle, R., Lim, C.K., Luo, J.L., Howells, L., Plummer, S., Jukes, R., Williams, M. and Steward, W.P., 2001. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. *Cancer Research*, 61(3), pp.1058-1064.

Irving, G.R., Karmokar, A., Berry, D.P., Brown, K. and Steward, W.P., 2011. Curcumin: the potential for efficacy in gastrointestinal diseases. *Best practice & research Clinical gastroenterology*, 25(4), pp.519-534.

Kumar, V., Cotran, R.S. and Robbins, S.L., 2007. Buku ajar patologi. *Jakarta: eGC*, pp.80-2.

Laurence, D.R. and Bacharach, A.L. eds., 1964. *Evaluation of drug activities: pharmacometrics* (Vol. 1, pp. 183-205). New York: Academic press.

Letterio, J.J., Roberts A.B. (1998). *Regulation of immune responses by TGF- β 1*. *Ann Rev of Immunology*, Vol. 16:137-161

Li, L., Hu, Z., Li, W., Hu, M., Ran, J., Chen, P. and Sun, Q. (2012). Establishment of a Standardized Liver Fibrosis Model with Different Pathological Stages in Rats. *Gastroenterology Research and Practice*, 2012, pp.1-6.

Lin, Y.L., Lin, C.Y., Chi, C.W. and Huang, Y.T., 2009. Study on antifibrotic effects of curcumin in rat hepatic stellate cells. *Phytotherapy Research*, 23(7), pp.927-932.

Liu, X., Xu, J., Brenner, D.A. and Kisseleva, T., 2013. Reversibility of liver fibrosis and inactivation of fibrogenic myofibroblasts. *Current pathobiology reports*, 1(3), pp.209-214.

López-Lázaro, M., 2008. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. *Molecular nutrition & food research*, 52(S1), pp.S103-S127.

Moreira, R. (2007). Hepatic Stellate Cells and Liver Fibrosis. *Archives of Pathology and Laboratory Medicine*, 131(11), pp.1728-1734.

Mormone, E., George, J. and Nieto, N. (2011). Molecular pathogenesis of hepatic

fibrosis and current therapeutic approaches. *Chemico-Biological Interactions*, 193(3), pp.225-231.

Moseley, T., Haudenschild, D., Rose, L. and Reddi, A. (2003). Interleukin-17 family and IL-17 receptors. *Cytokine & Growth Factor Reviews*, 14(2), pp.155-174.

Musthofiyah, Hidayatul. 2008. *Pengaruh Pemberian Buah Pepaya (Carica papaya) Terhadap Kadar Enzim Transaminase GOT-GPT dan Gambaran Histologi Hepar Mencit (Mus musculus) yang Diinduksi Karbontetraklorida (ccl4)*. Skripsi. Fakultas Sains dan Teknologi. Universitas Islam Negeri Malang. Diakses tanggal 16 desember 2013

Pellicoro, A., Ramachandran, P. and Iredale, J.P., 2012. Reversibility of liver fibrosis. *Fibrogenesis & tissue repair*, 5(1), p.1.

Pan, M.H., Huang, T.M. and Lin, J.K., 1999. Biotransformation of curcumin through reduction and glucuronidation in mice. *Drug metabolism and disposition*, 27(4), pp.486-494.

Park, H., Li, Z., Yang, X., Chang, S., Nurieva, R., Wang, Y., Wang, Y., Hood, L., Zhu, Z., Tian, Q. and Dong, C. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. *Nat Immunol*, 6(11), pp.1133-1141.

Poli, G., 2000. Pathogenesis of liver fibrosis: role of oxidative stress. *Molecular aspects of medicine*, 21(3), pp.49-98.

Poynard, T., Ngo, Y., Perazzo, H., Munteanu, M., Lebray, P., Moussalli, J., Thabut, D., Benhamou, Y. and Ratziau, V., 2011. Prognostic value of liver

fibrosis biomarkers: a meta-analysis. *Gastroenterol Hepatol (NY)*, 7(7), pp.445-54.

Poynard, T., Lebray, P., Ingiliz, P., Varaut, A., Varsat, B., Ngo, Y., Norha, P., Munteanu, M., Drane, F., Messous, D. and Bismut, F.I., 2010. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). *BMC gastroenterology*, 10(1), p.40.

Ramaiah SK. 2007. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters. *Food Chem. Toxicol.* 45, 1551–1557.

Rabson, A., Roitt, I.M. and Delves, P.J., 2005. *Really essential medical immunology*. Blackwell Pub..

Rivera-Espinoza, Y. and Muriel, P., 2009. Pharmacological actions of curcumin in liver diseases or damage. *Liver international*, 29(10), pp.1457-1466.

Rockey, D. (2008). Current and Future Anti-Fibrotic Therapies for Chronic Liver Disease. *Clinics in Liver Disease*, 12(4), pp.939-962.

Romero-Hernández, M.A., Eguía-Aguilar, P., Pérezpeña-DíazConti, M., Rodríguez-Leviz, A., Sadowinski-Pine, S., Velasco-Rodríguez, L.A., Cáceres-Cortés, J.R. and Arenas-Huertero, F., 2013. Toxic effects induced by curcumin in human astrocytoma cell lines. *Toxicology mechanisms and methods*, 23(9), pp.650-659.

Rivera-Espinoza, Y. and Muriel, P., 2009. Pharmacological actions of curcumin in liver diseases or damage. *Liver international*, 29(10), pp.1457-1466.

Roth, S., Michel, K. and Gressner, A.M., 1998. (Latent) transforming growth

factor β in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. *Hepatology*, 27(4), pp.1003-1012.

Seki, E., De Minicis, S., Österreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A. and Schwabe, R.F., 2007. TLR4 enhances TGF- β signaling and hepatic fibrosis. *Nature medicine*, 13(11), pp.1324-1332.

Shen, L. and Ji, H.F., 2009. Insights into the inhibition of xanthine oxidase by curcumin. *Bioorganic & medicinal chemistry letters*, 19(21), pp.5990-5993.

Shen, L. and Ji, H.F., 2012. The pharmacology of curcumin: is it the degradation products?. *Trends in molecular medicine*, 18(3), pp.138-144.

Shang, Y.J., Jin, X.L., Shang, X.L., Tang, J.J., Liu, G.Y., Dai, F., Qian, Y.P., Fan, G.J., Liu, Q. and Zhou, B., 2010. Antioxidant capacity of curcumin-directed analogues: Structure–activity relationship and influence of microenvironment. *Food Chemistry*, 119(4), pp.1435-1442.

Slater, T.F., Cheeseman, K.H., Ingold, K.U., Rice-Evans, C. and Sies, H., 1985. Carbon Tetrachloride Toxicity as a Model for Studying Free-Radical Mediated Liver Injury [and Discussion]. *Philosophical Transactions of the Royal Society of London B: Biological Sciences*, 311(1152), pp.633-645.

Slater, T.F., 1988. Free radical mechanisms in tissue injury. In *Cell Function and Disease* (pp. 209-218). Springer US.

Sies, H., Cadenas, E., Symons, M.C.R. and Scott, G., 1985. Oxidative stress: Damage to intact cells and organs [and discussion]. *Philosophical Transactions of the Royal Society of London B: Biological sciences*, 311(1152), pp.617-631.

Sugiyama, A., Nagaki, M., Shidoji, Y., Moriwaki, H. and Muto, Y., 1997. Regulation of cell cycle-related genes in rat hepatocytes by transforming growth factor β 1. *Biochemical and biophysical research communications*, 238(2), pp.539-543.

Suarsana dan Budiasa. 2005. *Potensi Hepatoproteksi Ekstrak Mengkudu pada Keracunan Parasetamol*. Jurnal Penelitian. Bali. Fakultas Kedokteran. Universitas Udayana

Tomasi, A., Albano, E., Banni, S., Botti, B., Corongiu, F., Dessi, M.A., Iannone, A., Vannini, V. and Dianzani, M.U., 1987. Free-radical metabolism of carbon tetrachloride in rat liver mitochondria. A study of the mechanism of activation. *Biochemical Journal*, 246(2), pp.313-317.

Wake, K., 1980. Perisinusoidal stellate cells (fat-storing cells, interstitial cells, lipocytes), their related structure in and around the liver sinusoids, and vitamin A-storing cells in extrahepatic organs. *International review of cytology*.

Wijayati, R., 2002. Analisis Penggunaan Hepatoprotektor Pada Terapi Hepatitis Di Instalasi Rawat Inap Rumah Sakit Angkatan Laut Dr. Ramelan Surabaya.

Williams, A.T. and Burk, R.F., 1990, November. Carbon tetrachloride hepatotoxicity: an example of free radical-mediated injury. In *Seminars in*

liver disease (Vol. 10, No. 04, pp. 279-284). © 1990 by Thieme Medical Publishers, Inc..

Wu, J.Y., Lin, C.Y., Lin, T.W., Ken, C.F. and Wen, Y.D., 2007. Curcumin affects development of zebrafish embryo. *Biological and Pharmaceutical Bulletin*, 30(7), pp.1336-1339.

Yaziji, H. and Barry, T., 2006. Diagnostic immunohistochemistry: what can go wrong?. *Advances in anatomic pathology*, 13(5), pp.238-246.

Yang, L., Wang, C., Ye, J. and Li, H. (2011). Hepatoprotective effects of polyphenols from Ginkgo biloba L. leaves on CCl₄-induced hepatotoxicity in rats. *Fitoterapia*, 82(6), pp.834-840.

Yao, Q.Y., Xu, B.L., Wang, J.Y., Liu, H.C., Zhang, S.C. and Tu, C.T., 2012. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. *BMC complementary and alternative medicine*, 12(1), p.156.

Zheng, S. and Chen, A., 2006. Curcumin suppresses the expression of extracellular matrix genes in activated hepatic stellate cells by inhibiting gene expression of connective tissue growth factor. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 290(5), pp.G883-G893.

Ziol, M., Handra-Luca, A., Kettaneh, A., Christidis, C., Mal, F., Kazemi, F., de Lédinghen, V., Marcellin, P., Dhumeaux, D., Trinchet, J.C. and Beaugrand, M., 2005. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. *Hepatology*, 41(1), pp.48-54.